Company Overview and News

 
Kingston Resources finds visible gold-bearing veins at prospect near Misima Gold Project

2018-09-26 proactiveinvestors.com.au
Kingston Resources Ltd (ASX:KSN) has found two visible gold-bearing veins near-surface in trenching and mapping work at its Ginamwamwa prospect in Papua New Guinea.
KSN

 
Kingston Resources finds up to 8.45 g/t at historic Ara Creek mine in PNG’s Misima North

2018-09-18 proactiveinvestors.com.au
Kingston Resources Ltd (ASX:KSN) has shared auger assays of up to 4.18 g/t gold from a prospect at its flagship Misima Gold Project in Papua New Guinea.
KSN

 
Kingston Resources back to drilling at Livingstone Gold Project

2018-09-10 proactiveinvestors.com.au
Kingston Resources Ltd (ASX:KSN) has resumed drilling at the Livingstone Gold Project, northwest of Meekatharra in Western Australia, with contractors mobilising at site last week.
KSN

 
Kingston Resources results confirm high-grade gold zones at Livingstone project

2018-08-21 proactiveinvestors.com.au
Kingston Resources Ltd (ASX:KSN) has received high-grade gold results in final assays from drilling at the Livingstone project in Western Australia which confirm broad gold zones.
KSN

 
Kingston Resources sampling shows potential to add to 2.8 million ounce Misima gold bounty

2018-08-14 proactiveinvestors.com.au
Kingston Resources Ltd (ASX:KSE) has received positive sampling results which indicate potential to add to the 2.8 million ounce gold resource at the Misima project in Papua New Guinea.
KSN

1
Lithium Miners News For The Month Of July 2018

2018-07-25 seekingalpha
Lithium market - Goldman: Concerns about a wave of supply of the electric car battery material from new mines are unfounded. The selloff in companies tied to lithium is overdone.
LIT BCN PILBF LTHHF CXO SAV LAXXF LIACF AGY NMT KSN PLLLY RDRUY AZZVF WML MLNLF AIS.H KDR DFS SYA STLHF WMLLF LNRDY NGZ LMMFF GXY TAW LRS MNIKF ILHMF AMLM DMNXF MALRY BGS LACDF EEYMF MIN NMKEF ARYMF ILC GALXF MGXMF LSSCF ALTAF DJIFF NMX EMH PSC CRECF OROCF ERPNF LAC PLS FTI.WI FMC BCN TWNAF DJI RRSSF PDDTF NTTHF AVLIF MALRF ORE AVZ AJM BCRMF

 
Kingston Resources confirms broad gold zones at its Livingstone Gold Project

2018-07-03 proactiveinvestors.com.au
Kingston Resources Ltd (ASX:KSN) has defined broad zones of gold mineralisation over a strike length of 2.2 kilometres at is Livingstone Gold Project in Western Australia’s Mid West region.
KSN

1
Galaxy strengthens Mt Cattlin presence with acquisition

2018-06-24 australianmining.com.au
Galaxy Resources has added lithium tenements at Mt Cattlin in Western Australia through the acquisition of assets owned by Kingston Resources.
KSN GXY GALXF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...